Claims
- 1. A composition of matter selected from the group consisting of:
a) a substantially pure or recombinant CKDLR20.1 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 2; b) a natural polypeptide sequence CKDLR20.1 of SEQ ID NO: 2; c) a fusion protein comprising sequence or SEQ ID NO: 2; d) a substantially pure or recombinant 69A08 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 4 or 6; e) a natural sequence 69A08 of SEQ ID NO: 4 or 6; f) a fusion protein comprising sequence of SEQ ID NO: 4 or 6; g) a substantially pure or recombinant HSD12 protein or peptide exhibiting at least about 85% sequence identity over a length of at least about 12 amino acids to SEQ ID NO: 8; h) a natural sequence HSD12 of SEQ ID NO: 8; or i) a fusion protein comprising sequence of SEQ ID NO: 8.
- 2. A substantially pure or isolated protein comprising:
A) a segment exhibiting sequence identity to a corresponding portion of a CKDLR20.1 of claim 1, wherein:
a) said homology is at least about 90% identity and said portion is at least about 9 amino acids; b) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or c) said homology is at least about 70% identity and said portion is at least about 25 amino acids; B) a segment exhibiting sequence identity to a corresponding portion of a 69A08 receptor of claim 1, wherein:
a) said homology is at least about 90% identity and said portion is at least about 9 amino acids; b) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or c) said homology is at least about 70% identity and said portion is at least about 25 amino acids; or C) a segment exhibiting sequence identity to a corresponding portion of an HSD12 receptor of claim 1, wherein:
a) said homology is at least about 90% identity and said portion is at least about 9 amino acids; b) said homology is at least about 80% identity and said portion is at least about 17 amino acids; or c) said homology is at least about 70% identity and said portion is at least about 25 amino acids.
- 3. The composition of matter of claim 1, wherein said:
A) protein is CKDLR20.1; and
a) said CKDLR20.1 comprises a mature sequence of Table 1; or b) said protein or peptide:
i) is from a warm blooded animal selected from a mammal, including a rodent; ii) comprises at least one polypeptide segment of SEQ ID NO: 2; iii) exhibits a plurality of portions exhibiting said identity; iv) is a natural allelic variant of CKDLR20.1; v) has a length at least about 30 amino acids; vi) exhibits at least two non-overlapping epitopes which are specific for a mammalian CKDLR20.1; vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a rodent CKDLR20.1; viii) exhibits at least two non-overlapping epitopes which are specific for a rodent CKDLR20.1; ix) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a rodent CKDLR20.1; x) is glycosylated; xi) is a synthetic polypeptide; xii) is attached to a solid substrate; xiii) is conjugated to another chemical moiety; xiv) is a 5-fold or less substitution from natural sequence; or xv) is a deletion or insertion variant from a natural sequence; B) protein is 69A08; and
a) said 69A08 comprises a mature sequence of Table 2; or b) said protein or peptide:
i) is from a warm blooded animal selected from a mammal, including a rodent; ii) comprises at least one polypeptide segment of SEQ ID NO: 4 or 6; iii) exhibits a plurality of portions exhibiting said identity; iv) is a natural allelic variant of rodent 69A08; v) has a length at least about 30 amino acids; vi) exhibits at least two non-overlapping epitopes which are specific for a mammalian 69A08; vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a rodent 69A08; viii) exhibits at least two non-overlapping epitopes which are specific for a rodent 69A08; ix) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a rodent 69A08; x) is glycosylated; xi) is a synthetic polypeptide; xii) is attached to a solid substrate; xiii) is conjugated to another chemical moiety; xiv) is a 5-fold or less substitution from natural sequence; or xv) is a deletion or insertion variant from a natural sequence; or C) protein is HSD12; and
a) said HSD12 comprises a mature sequence of Table 3; or b) said protein or peptide:
i) is from a warm blooded animal selected from a mammal, including a primate; ii) comprises at least one polypeptide segment of SEQ ID NO: 8; iii) exhibits a plurality of portions exhibiting said identity; iv) is a natural allelic variant of HSD12; v) has a length at least about 30 amino acids; vi) exhibits at least two non-overlapping epitopes which are specific for a mammalian HSD12; vii) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate HSD12; viii) exhibits at least two non-overlapping epitopes which are specific for a primate HSD12; ix) exhibits a sequence identity at least about 90% over a length of at least about 20 amino acids to a primate HSD12; x) is glycosylated; xi) is a synthetic polypeptide; xii) is attached to a solid substrate; xiii) is conjugated to another chemical moiety; xiv) is a 5-fold or less substitution from natural sequence; or xv) is a deletion or insertion variant from a natural sequence;
- 4. A composition comprising:
a) a sterile CKDLR20.1 protein or peptide of claim 1;b) said CKDLR20.1 protein or peptide of claim 1 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration; c) a sterile 69A08 protein or peptide of claim 1;d) said 69A08 protein or peptide of claim 1 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration; e) a sterile 69A08 protein or peptide of claim 1; or f) said HSD12 protein or peptide of claim 1 and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration.
- 5. The fusion protein of claim 1, comprising:
a) mature protein sequence of Table 1; b) mature protein sequence of Table 2; c) mature protein sequence of Table 3; d) a detection or purification tag, including a FLAG, His6, or Ig sequence; e) sequence of another chemokine protein; or f) sequence of another G protein coupled receptor protein.
- 6. A kit comprising:
A) a CKDLR20.1 protein or polypeptide of claim 1, and:
a) a compartment comprising said protein or polypeptide; and/or b) instructions for use or disposal of reagents in said kit; B) a 69A08 protein or polypeptide of claim 1, and:
a) a compartment comprising said protein or polypeptide; and/or b) instructions for use or disposal of reagents in said kit; or C) an HSD12 protein or polypeptide of claim 1, and:
a) a compartment comprising said protein or polypeptide; and/or b) instructions for use or disposal of reagents in said kit.
- 7. A binding compound comprising an antigen binding portion from an antibody, which specifically binds to:
A) a natural CKDLR20.1 protein of claim 1, wherein:
a) said protein is a rodent protein; b) said binding compound is an Fv, Fab, or Fab2 fragment; c) said binding compound is conjugated to another chemical moiety; or d) said antibody:
i) is raised against a peptide sequence of a mature polypeptide comprising sequence of Table 1; ii) is raised against a mature CKDLR20.1; iii) is raised to a purified CKDLR20.1; iv) is immunoselected; v) is a polyclonal antibody; vi) binds to a denatured CKDLR20.1; vii) exhibits a Kd to antigen of at least 30 μM; viii) is attached to a solid substrate, including a bead or plastic membrane; ix) is in a sterile composition; or x) is detectably labeled, including a radioactive or fluorescent label; B) a natural 69A08 protein of claim 1, wherein:
a) said protein is a rodent protein; b) said binding compound is an Fv, Fab, or Fab2 fragment; c) said binding compound is conjugated to another chemical moiety; or d) said antibody:
i) is raised against a peptide sequence of a mature polypeptide comprising sequence of Table 2; ii) is raised against a mature 69A08; iii) is raised to a purified 69A08; iv) is immunoselected; v) is a polyclonal antibody; vi) binds to a denatured 69A08; vii) exhibits a Kd to antigen of at least 30 μM; viii) is attached to a solid substrate, including a bead or plastic membrane; ix) is in a sterile composition; or x) is detectably labeled, including a radioactive or fluorescent label; or C) a natural HSD12 protein of claim 1, wherein:
a) said protein is a primate protein; b) said binding compound is an Fv, Fab, or Fab2 fragment; c) said binding compound is conjugated to another chemical moiety; or d) said antibody:
i) is raised against a peptide sequence of a mature polypeptide comprising sequence of Table 3; ii) is raised against a mature HSD12; iii) is raised to a purified HSD12; iv) is immunoselected; v) is a polyclonal antibody; vi) binds to a denatured HSD12; vii) exhibits a Kd to antigen of at least 30 μM; viii) is attached to a solid substrate, including a bead or plastic membrane; ix) is in a sterile composition; or x) is detectably labeled, including a radioactive or fluorescent label; or
- 8. A kit comprising said binding compound of:
A) claim 7A, and:
a) a compartment comprising said binding compound; and/or b) instructions for use or disposal of reagents in said kit; B) claim 7B, and:
a) a compartment comprising said binding compound; and/or b) instructions for use or disposal of reagents in said kit; or C) claim 7C, and:
a) a compartment comprising said binding compound; and/or b) instructions for use or disposal of reagents in said kit.
- 9. A method of producing an antigen:antibody complex, comprising contacting:
a) a CKDLR20.1 protein or peptide with an antibody of claim 7A; b) a 69A08 protein or peptide with an antibody of claim 7B; or c) an HSD12 protein or peptide-with an antibody of claim 7C; thereby allowing said complex to form.
- 10. The method of claim 9, wherein:
a) said complex is purified from other chemokine or chemokine receptor; b) said complex is purified from other antibody; c) said contacting is with a sample comprising said CKDLR20.1 chemokine antigen; d) said contacting is with a sample comprising said 69A08 or HSD12 receptor antigen; e) said contacting allows quantitative detection of said antigen; f) said contacting is with a sample comprising said antibody; or g) said contacting allows quantitative detection of said antibody.
- 11. A composition comprising:
a) a sterile binding compound of claim 7A, or b) said binding compound of claim 7A and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration; c) a sterile binding compound of claim 7B, or d) said binding compound of claim 7B and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration; e) a sterile binding compound of claim 7C, or f) said binding compound of claim 7C and a carrier, wherein said carrier is:
i) an aqueous compound, including water, saline, and/or buffer; and/or ii) formulated for oral, rectal, nasal, topical, or parenteral administration.
- 12. An isolated or recombinant nucleic acid encoding a protein or peptide or fusion protein of claim 1, wherein:
A) said protein or polypeptide is CKDLR20.1 and:
a) said CKDLR20.1 protein is from a mammal, including a rodent; or b) said nucleic acid:
i) encodes an antigenic peptide sequence of Table 1; ii) encodes a plurality of antigenic peptide sequences of Table 1; iii) exhibits at least about 80% identity to a natural cDNA encoding said segment; iv) comprises a stretch exhibiting at least 80% identity to the mature open reading frame from SEQ ID NO: 1; v) is an expression vector; vi) further comprises an origin of replication; vii) is from a natural source; viii) comprises a detectable label; ix) comprises synthetic nucleotide sequence; x) is less than 6 kb, preferably less than 3 kb; xi) is from a mammal, including a primate; xii) comprises a natural full length coding sequence; xiii) is a hybridization probe for a gene encoding said CKDLR20.1 protein; or xiv) is a PCR primer, PCR product, or mutagenesis primer; B) said protein or polypeptide is 69A08 and:
a) said 69A08 protein is from a mammal, including a rodent; or b) said nucleic acid:
i) encodes an antigenic peptide sequence of Table 2; ii) encodes a plurality of antigenic peptide sequences of Table 2; iii) exhibits at least about 80% identity to a natural cDNA encoding said segment; iv) comprises a stretch exhibiting at least 80% identity to the mature open reading frame from SEQ ID NO: 3 or 5; v) is an expression vector; vi) further comprises an origin of replication; vii) is from a natural source; viii) comprises a detectable label; ix) comprises synthetic nucleotide sequence; x) is less than 6 kb, preferably less than 3 kb; xi) is from a mammal, including a primate; xii) comprises a natural full length coding sequence; xiii) is a hybridization probe for a gene encoding said 69A08 protein; or xiv) is a PCR primer, PCR product, or mutagenesis primer; or C) said protein or polypeptide is HSD12 and:
a) said HSD12 protein is from a mammal, including a primate; or b) said nucleic acid:
i) encodes an antigenic peptide sequence of Table 3; ii) encodes a plurality of antigenic peptide sequences of Table 3; iii) exhibits at least about 80% identity to a natural cDNA encoding said segment; iv) comprises a stretch exhibiting at least 80% identity to the mature open reading frame from SEQ ID NO: 7; v) is an expression vector; vi) further comprises an origin of replication; vii) is from a natural source; viii) comprises a detectable label; ix) comprises synthetic nucleotide sequence; x) is less than 6 kb, preferably less than 3 kb; xi) is from a mammal, including a primate; xii) comprises a natural full length coding sequence; xiii) is a hybridization probe for a gene encoding said HSD12 protein; or xiv) is a PCR primer, PCR product, or mutagenesis primer.
- 13. A cell or tissue comprising a recombinant nucleic acid of claim 12A, 12B, or 12C.
- 14. The cell of claim 13, wherein said cell is:
a) a prokaryotic cell; b) a eukaryotic cell; c) a bacterial cell; d) a yeast cell; e) an insect cell; f) a mammalian cell; g) a mouse cell; h) a primate cell; or i) a human cell.
- 15. A kit comprising said nucleic acid:
A) of claim 12A, and:
a) a compartment comprising said nucleic acid; b) a compartment further comprising a CKDLR20.1 protein or polypeptide; and/or b) instructions for use or disposal of reagents in said kit; B) of claim 12B, and:
a) a compartment comprising said nucleic acid; b) a compartment further comprising a 69A08 protein or polypeptide; and/or b) instructions for use or disposal of reagents in said kit; or C) of claim 12C, and:
a) a compartment comprising said nucleic acid; b) a compartment further comprising an HSD12 protein or polypeptide; and/or b) instructions for use or disposal of reagents in said kit.
- 16. A nucleic acid of which:
a) hybridizes under wash conditions of 30° C. and less than 2M salt to SEQ ID NO: 1; b) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a rodent CKDLR20.1; c) hybridizes under wash conditions of 30° C. and less than 2M salt to SEQ ID NO: 3 or 5; d) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a rodent 69A08; e) hybridizes under wash conditions of 30° C. and less than 2M salt to SEQ ID NO: 7; or f) exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate HSD12.
- 17. The nucleic acid of claim 16, wherein:
a) said wash conditions are at 45° C. and/or 500 mM salt; or b) said identity is at least 90% and/or said stretch is at least 55 nucleotides.
- 18. The nucleic acid of claim 17, wherein:
a) said wash conditions are at 55° C. and/or 150 mM salt; or b) said identity is at least 95% and/or said stretch is at least 75 nucleotides.
- 19. A method of producing a ligand:receptor complex, comprising contacting:
a) a protein made by expression of a nucleic acid of claim 12A with a G protein coupled receptor; b) a protein or peptide made by expression of a nucleic acid of claim 12B with a chemokine or ligand; or c) a protein or peptide made by expression of a nucleic acid of claim 12C with a chemokine or ligand; thereby allowing said complex to form.
- 20. The method of claim 19, wherein:
a) said complex results in a Ca++ flux; b) said G protein coupled receptor is on a cell; c) said complex results in a physiological change in a cell expressing said receptor or protein; d) said 69A08 or HSD12 protein is on a cell; e) said contacting is with a sample comprising a chemical antagonist to block production of said complex; or f) said contacting allows quantitative detection of said ligand.
Parent Case Info
[0001] The present filing is a conversion of provisional U.S. patent application Ser. No. 60/035,956, filed Jan. 21, 1997, which is incorporated herein by reference, to a U.S. Utility patent application.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60035956 |
Jan 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09009817 |
Jan 1998 |
US |
Child |
09943718 |
Aug 2001 |
US |